» Articles » PMID: 31650522

Predictors of Left Ventricular Dysfunction in Friedreich's Ataxia in a 16-Year Observational Study

Overview
Date 2019 Oct 26
PMID 31650522
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Friedreich's ataxia (FRDA) is a cerebellar ataxia due to GAA repeat expansions in the FXN gene, and in affected patients, lower left ventricular ejection fraction (LVEF) leads to poorer prognosis. We aimed to identify patients likely to develop worsening LVEF at an early stage.

Methods: We included 115 FRDA patients aged 30 ± 10 years with 620 ± 238 GAA repeats on the shorter allele and disease onset of 15 ± 7 years.

Results: At baseline, left ventricular (LV) hypertrophy was present in 53%, with LVEF 65 ± 7%, LV end diastolic diameter (LVEDD) 43 ± 5 mm, septal wall thickness (SWT) 11.8 ± 2.7 mm, and posterior wall thickness 11.1 ± 2.5 mm. After a mean follow-up of 13 ± 6 years, LVEF ≤ 50% was observed in 12 patients. The main determinants of LVEF ≤ 50% were GAA repeat number on the shorter allele (odds ratio [OR] 1.007, 95% confidence interval [CI] 1.003-1.012, p = 0.002), LVEDD (OR 1.217, 95% CI 1.058-1.399, p = 0.006), and SWT (OR 1.352, 95% CI 1.016-1.799, p = 0.04). High-risk patients were predicted 5 years before LVEF ≤ 50% occurred: area under the curve of 0.91, 95% CI 0.85-0.97. Patients with GAA repeats > 800 were categorized as high risk, patients with 500 < GAA < 800 were high risk if LVEDD was ≥ 52.6 mm and SWT was ≥ 13.3 mm, and patients with GAA < 500 were low risk if LVEDD was < 52.6 mm and SWT was < 13.3 mm.

Conclusions: Echocardiographic follow-up combined with size assessment of GAA repeat expansions is a powerful tool to identify patients at high risk of developing LV systolic dysfunction up to 5 years before clinical symptoms. Further studies are mandatory to investigate if these patients would benefit from cardiac interventions.

Citing Articles

New and Emerging Drug and Gene Therapies for Friedreich Ataxia.

Scott V, Delatycki M, Tai G, Corben L CNS Drugs. 2024; 38(10):791-805.

PMID: 39115603 PMC: 11377510. DOI: 10.1007/s40263-024-01113-z.


Insights into the effects of Friedreich ataxia on the left ventricle using T1 mapping and late gadolinium enhancement.

Peverill R, Lin K, Fogel M, Cheung M, Moir W, Corben L PLoS One. 2024; 19(5):e0303969.

PMID: 38814901 PMC: 11139319. DOI: 10.1371/journal.pone.0303969.


Neuromuscular diseases and their cardiac manifestations under the spectrum of cardiovascular imaging.

Alexandridis G, Pagourelias E, Fragakis N, Kyriazi M, Vargiami E, Zafeiriou D Heart Fail Rev. 2022; 27(6):2045-2058.

PMID: 35857244 DOI: 10.1007/s10741-022-10260-8.


Body Mass Index and Height in the Friedreich Ataxia Clinical Outcome Measures Study.

Patel M, McCormick A, Tamaroff J, Dunn J, Mitchell J, Lin K Neurol Genet. 2021; 7(6):e638.

PMID: 34786480 PMC: 8589265. DOI: 10.1212/NXG.0000000000000638.


Adaptation of the heart to Frataxin depletion: Evidence that integrated stress response can predominate over mTORC1 activation.

Vasquez-Trincado C, Patel M, Sivaramakrishnan A, Bekeova C, Anderson-Pullinger L, Wang N Hum Mol Genet. 2021; .

PMID: 34550363 PMC: 11000666. DOI: 10.1093/hmg/ddab216.